Scholar Rock Holding (SRRK) Interest & Investment Income (2024 - 2026)
Scholar Rock Holding (SRRK) posted quarterly Interest & Investment Income of $2.9 million for Q1 2026, down 30.6% year-over-year from $4.2 million in Q1 2025, and down 16.76% quarter-over-quarter from $3.5 million in Q4 2025.
Analysis
Scholar Rock Holding (SRRK) Interest & Investment Income (2024 - 2026) Analysis & Trends
Scholar Rock Holding's Interest & Investment Income history runs 3 years deep, the most recent figure standing at $2.9 million for Q1 2026.
- In Q1 2026, Interest & Investment Income fell 30.6% year-over-year to $2.9 million; the TTM figure through Mar 2026 stood at $12.6 million (down 7.26% YoY), while the FY2025 annual figure was $13.9 million, up 9.6% from the prior year.
- Interest & Investment Income for Q1 2026 stood at $2.9 million, down from $3.5 million in the prior quarter.
- The five-year high for Interest & Investment Income was $4.6 million in Q4 2024, with the low at $2.1 million in Q3 2024.
- The 3-year median for Interest & Investment Income is $3.3 million (2024), against an average of $3.3 million.
- The sharpest annual moves came in 2025 and 2026: Interest & Investment Income jumped 31.2% in 2025, then slumped 30.6% in 2026.
- Scholar Rock Holding's Interest & Investment Income stood at $4.6 million in 2024, then retreated by 22.69% to $3.5 million in 2025, then fell by 16.76% to $2.9 million in 2026.
- Business Quant data shows SRRK's Interest & Investment Income at $2.9 million in Q1 2026, $3.5 million in Q4 2025, and $2.7 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.26 Bn | 131.41 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.64 Bn | 77.64 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 57.83 Bn | 52.69 Bn | 52.00 Mn | 67.00 Mn |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | 35.58 Mn |
| 6 | BeOne Medicines | 39.94 Bn | 34.84 Bn | 1.53 Bn | 27.90 Mn |
| 7 | Alnylam Pharmaceuticals | 35.19 Bn | 31.88 Bn | 992.69 Mn | 28.14 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | 5.13 Mn |
| 9 | Insmed | 27.35 Bn | 26.19 Bn | 358.27 Mn | 10.98 Mn |
| 10 | Scholar Rock Holding | 7.20 Bn | 7.20 Bn | - | 4.09 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 4.09 Mn |
| Mar 31, 2026 | 2.94 Mn |
| Dec 31, 2025 | 3.53 Mn |
| Sep 30, 2025 | 2.73 Mn |
| Jun 30, 2025 | 3.41 Mn |
| Mar 31, 2025 | 4.23 Mn |
| Dec 31, 2024 | 4.56 Mn |
| Sep 30, 2024 | 2.08 Mn |
| Jun 30, 2024 | 2.72 Mn |
| Mar 31, 2024 | 3.32 Mn |